Lutathera (lutetium Lu 177 dotatate) - Novartis
Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumours with [ 177 Lu]Lu-DOTA-TATE Therapy (EANM 2026) - Sep 29, 2026 - Abstract #EP-0880; "All three Bellmunt-based risk scores demonstrated significant prognostic value for OS. The eBRS achieved the best discriminatory capacity, while the mBRS offered the most detailed clinical risk stratification. These findings support the applicability of adapted Bellmunt scoring systems as prognostic tools in the PRRT setting." 
Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • CRP
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
E. Dema 1; S. C. Siegmund 1; F. J. Gildehaus 1; C. Spitzweg 2; C. J. Auernhammer 2; R. A. Werner 1
 
Sep 29, 2026
 
Prev Next